Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Samsung BioLogics says report on Biogen deal talks untrue

Published 12/29/2021, 02:54 PM
Updated 12/30/2021, 11:31 AM
© Reuters. FILE PHOTO: Employees of Samsung Group work at the company's headquarters in Seoul April 22, 2008. REUTERS/Jo Yong-Hak
BIIB
-
HAR
-
005930
-
SSNLF
-

(Reuters) - Samsung (KS:005930) BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc (NASDAQ:BIIB).

Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.

Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.

Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.

Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics (OTC:SSNLF) bought auto electronics maker Harman International Industries (D:HAR) in an $8 billion deal.

Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.

In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.

Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.

© Reuters. FILE PHOTO: Employees of Samsung Group work at the company's headquarters in Seoul April 22, 2008. REUTERS/Jo Yong-Hak

But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.

Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.